Сравнение

Lanreotid vs. Pasireotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

108736-35-2

396091-73-9

Молекулярная масса

1096.34 g/mol

1047.21 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Lanreotid

Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Lanreotid	Pasireotid
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Lanreotid and Pasireotid?: Lanreotid is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Lanreotid or Pasireotid?: The highest available evidence level is "РКИ на людях" for Lanreotid and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Lanreotid and Pasireotid in Germany and the United States?: Германия: Lanreotid — Рецептурный, Pasireotid — Рецептурный. США: Lanreotid — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Lanreotid

Pasireotid

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Lanreotid and Pasireotid?

Lanreotid is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Lanreotid or Pasireotid?

The highest available evidence level is "РКИ на людях" for Lanreotid and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Lanreotid and Pasireotid in Germany and the United States?

Германия: Lanreotid — Рецептурный, Pasireotid — Рецептурный. США: Lanreotid — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.